Cardiac risks associated with antibiotics: azithromycin and levofloxacin

Bibliography

• Hicks LA, Taylor THJr, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 2013;368(15):1461-2
   PubMed Web of Science ®Google Scholar
• IMS Institute for Healthcare Informatics. The use of medicines in the United States review of 2011. 2011
   Google Scholar
• Food and Drug Administration. Levaquin® Utilization Trends, January 2004 to March 2011. 2011
   Google Scholar
• Gilbert DN. Sanford guide to antimicrobial therapy. 43 edition. Antimicrobial Therapy; Sperryville, VA: 2013
   Google Scholar
• Food and Drug Administration. Zmax® (azithromycin) BPCA Drug Use Review. 2010
   Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20):1881-90
   PubMed Web of Science ®Google Scholar
• Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014;12(2):121-7
   PubMed Web of Science ®Google Scholar
• Federal Drug Comission. FDA/PhRMA task force to assess QT risk by preclinical markers. The Pink Sheet; Chevy Chase, MD: 1999
   Google Scholar
• Food and Drug Administration. FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. 2013
   Google Scholar
• Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368(18):1704-12
   PubMed Web of Science ®Google Scholar
• Bazett HC. An analysis of the time-relations of electrocardiograms. Ann Noninvasive Electrocardiol 1997;2(2):177-94
   Google Scholar
• Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47(2):362-7
   PubMed Web of Science ®Google Scholar
• Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348(19):1866-74
   PubMed Web of Science ®Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10):1013-22
   PubMed Web of Science ®Google Scholar
• Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354(9190):1625-33
   PubMed Web of Science ®Google Scholar
• Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55(9):934-47
   PubMed Web of Science ®Google Scholar
• Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Jama 1993;270(21):2590-7
   PubMed Web of Science ®Google Scholar
• Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf 2012;3(5):241-53
   PubMedGoogle Scholar
• Owens RCJr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006;43(12):1603-11
   PubMed Web of Science ®Google Scholar
• Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie 2010;65(9):631-40
   PubMed Web of Science ®Google Scholar
• Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99(12):1540-7
   PubMed Web of Science ®Google Scholar
• Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003;361(9360):809-13
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003;290(11):1459-66
   PubMed Web of Science ®Google Scholar
• Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352(16):1637-45
   PubMed Web of Science ®Google Scholar
• Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000;23(9):1433-5
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Garcia A, Mont L, Roque M. [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome]. Med Clin (Barc) 2001;117(3):118-19
   PubMed Web of Science ®Google Scholar
• Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006;77(1):30-2
   PubMedGoogle Scholar
• Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol 2005;28(11):1221-2
   PubMed Web of Science ®Google Scholar
• Samarendra P, Kumari S, Evans SJ, et al. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 2001;24(10):1572-4
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003;116(1185):U666
   PubMedGoogle Scholar
• Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 2007;30(12):1579-82
   PubMed Web of Science ®Google Scholar
• Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007;18(3):243-6
   PubMed Web of Science ®Google Scholar
• Del Rosario ME, Weachter R, Flaker GC. Drug-induced QT prolongation and sudden death. Mo Med 2010;107(1):53-8
   PubMedGoogle Scholar
• Santos N, Oliveira M, Galrinho A, et al. QT interval prolongation and extreme bradycardia after a single dose of azithromycin. Rev Port Cardiol 2010;29(1):139-42
   PubMedGoogle Scholar
• Winton JC, Twilla JD. Sudden cardiac arrest in a patient on chronic methadone after the addition of azithromycin. Am J Med Sci 2013;345(2):160-2
   PubMed Web of Science ®Google Scholar
• Strle F, Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr 2002;114(10-11):396-9
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2012
   Google Scholar
• Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014;311(21):2199-208
   PubMed Web of Science ®Google Scholar
• Paltoo B, O’Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001;24(5):895-7
   PubMed Web of Science ®Google Scholar
• Patel PD, Afshar H, Birnbaum Y. Levofloxacin-induced torsades de pointes. Tex Heart Inst J 2010;37(2):216-17
   PubMed Web of Science ®Google Scholar
• Gandhi PJ, Menezes PA, Vu HT, et al. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003;60(23):2479-83
   PubMed Web of Science ®Google Scholar
• Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005;39(3):543-6
   PubMed Web of Science ®Google Scholar
• Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11(1):52-6
   PubMed Web of Science ®Google Scholar
• Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73(4):292-303
   PubMed Web of Science ®Google Scholar
• Makaryus AN, Byrns K, Makaryus MN, et al. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant “clinical” event? South Med J 2006;99(1):52-6
   PubMed Web of Science ®Google Scholar
• Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128(5):3398-406
   PubMed Web of Science ®Google Scholar
• Juurlink DN. The cardiovascular safety of azithromycin. CMAJ 2014;186(15):1127-8
   PubMed Web of Science ®Google Scholar
• Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94(6):1471-4
   PubMed Web of Science ®Google Scholar
• Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280(20):1774-6
   PubMed Web of Science ®Google Scholar
• Pham TV, Sosunov EA, Anyukhovsky EP, et al. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation 2002;106(16):2132-6
   PubMed Web of Science ®Google Scholar
• Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res 2002;53(3):763-9
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996;94(10):2535-41
   PubMed Web of Science ®Google Scholar
• Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8(7):690-5
   PubMed Web of Science ®Google Scholar
• Pham TV, Sosunov EA, Gainullin RZ, et al. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 2001;103(17):2207-12
   PubMed Web of Science ®Google Scholar
• Albert RK, Schuller JL. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189(10):1173-80
   PubMed Web of Science ®Google Scholar
• Wright AJ, Gomes T, Mamdani MM, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011;183(3):303-7
   PubMed Web of Science ®Google Scholar
• Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35(2):197-200
   PubMed Web of Science ®Google Scholar
• Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303(1):218-25
   PubMed Web of Science ®Google Scholar
• Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 2001;87(3):231-4
   PubMedGoogle Scholar
• Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010;33(4):303-14
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Mathew J, Alexander JJ, et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368(18):1665-8
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. 2013
   Google Scholar
• Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89(11):1363-72
   PubMed Web of Science ®Google Scholar
• Gupta A, Lawrence AT, Krishnan K, et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153(6):891-9
   PubMed Web of Science ®Google Scholar
• Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009;66(9):825-33
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-98
   PubMed Web of Science ®Google Scholar
• Berg HF, Maraha B, Scheffer GJ, et al. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis 2005;40(3):358-65
   PubMed Web of Science ®Google Scholar
• Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Available from:http://www.pha.nu.ac.th/apirukw/dis/uploads/8BA9E_Citing_Micromedex.pdf
   Google Scholar
• Wong E, Nguyen TV. A case-based approach to evaluating azithromycin use and cardiovascular risks. Consult Pharm 2014;29(1):47-52
   PubMedGoogle Scholar